| Drugname |
Patent Number |
Patent Title |
Patent Assignee |
Estimated Expiration |
| Veliparib |
➤ Sign Up |
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
Signal Pharmaceuticals, LLC (San Diego, CA) |
➤ Sign Up |
| Veliparib |
➤ Sign Up |
1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
Abbott Laboratories Inc. (Abbott Park, IL) |
➤ Sign Up |
| Veliparib |
➤ Sign Up |
2-{(R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 2 |
Abbott Laboratories (Abbott Park, IL) |
➤ Sign Up |
| Veliparib |
➤ Sign Up |
2-{(R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 |
AbbVie Inc. (North Chicago, IL) |
➤ Sign Up |
| Veliparib |
➤ Sign Up |
Methods for treating ovarian cancer by inhibiting fatty acid binding proteins |
The University of Chicago (Chicago, IL) |
➤ Sign Up |
| Drugname |
Patent Number |
Patent Title |
Patent Assignee |
Estimated Expiration |
This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
